Assessing emerging technological innovation and collaborative strategies to drive time/cost efficiencies and valuable translational insights in non-clinical development
Examining risk mitigation best practices and exploring emerging challenges/opportunities for an expanding cell and gene therapy sector
Two decades on from the advent of commercial-scale protein therapeutics manufacture, is the viral vector space ready to make its own rapid advance towards industrialization?
Learning lessons from recent setbacks, utilizing novel technological innovation, and defining key steps from early development towards delivering robust data packages
How sustainable are the manufacturing and commercialization models of leaders in the cellular immunotherapy field?
How are cutting-edge R&D/technological innovation and a growing understanding of human and disease biology driving the expansion of gene therapy and gene editing into new, larger markets and indications?
Ensuring strategic and operational excellence in the increasingly competitive world of cell and gene therapy clinical development
Identifying and addressing critical scalability bottlenecks in cell therapy and viral vector bioprocessing and supply chain to enable large-scale manufacture of advanced therapies
Is recent innovation in analytical tools delivering the required improvements in cost, speed and accuracy for vector manufacturing?
An exploration of the cutting-edge in next-gen cell therapy technology platforms and applications spanning the cellular immunotherapy and stem cell therapy realms
How recent technological advances and economic/healthcare/regulatory evolution have helped ignite the centralized versus distributed manufacturing debate
Cell & Gene Therapy Insights’ annual review of the year just gone, with trends analysis providing pointers to the likely big stories and developments in the 12 months ahead.
Combined with an exploration of enabling tools and therapeutic technology platforms likely to make a splash in 2022.